Nebivolol Accord (Nebivolol Hydrochloride)

• Nebivolol Accord is a selective β1‑adrenergic antagonist indicated for cardiovascular conditions that require blood‑pressure control and cardiac workload reduction.
• Hypertension: lowers systolic and diastolic blood pressure by reducing heart rate and peripheral vascular resistance.
• Heart failure: improves cardiac output and reduces symptoms by decreasing myocardial oxygen demand and after‑load.

• Nebivolol Hydrochloride selectively blocks β1‑adrenergic receptors in cardiac tissue, decreasing heart rate and contractility. Concurrently, it stimulates endothelial nitric‑oxide release, causing vasodilation and lowering peripheral vascular resistance. The combined effect reduces cardiac workload and systemic blood pressure without significant β2‑receptor antagonism.

Nebivolol Accord may cause a range of adverse reactions.

Common Side Effects

• Headache: mild to moderate pain often occurring early in therapy.
• Dizziness: sensation of light‑headedness, especially upon standing.
• Fatigue: generalized tiredness or reduced energy.
• Bradycardia: slower than normal heart rate.
• Nasal congestion: blocked or runny nose.
• Diarrhea: loose stools occurring intermittently.

Serious or Rare Side Effects

• Severe bradycardia: markedly low heart rate requiring medical attention.
• Symptomatic hypotension: significant drop in blood pressure causing faintness.
• Heart block: impairment of electrical conduction in the heart.
• Bronchospasm: narrowing of airways, particularly in patients with asthma.
• Allergic reactions: rash, itching, swelling, or anaphylaxis.
• Hepatic dysfunction: abnormal liver enzyme elevations.

• Before initiating therapy, consider the following safety measures.
• Dose adjustment in renal impairment: reduce dose in patients with reduced kidney function.
• Caution in asthma or COPD: monitor for bronchospasm due to β‑blockade.
• Monitor heart rate and blood pressure: ensure values remain within therapeutic range.
• Avoid abrupt discontinuation: taper gradually to prevent rebound hypertension.
• Use with caution in diabetes: may mask hypoglycaemic symptoms.
• Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Nebivolol may interact with several drug classes, requiring clinical vigilance.

Major Interactions (Avoid)

• Concomitant use with other beta‑blockers: additive cardiac depression.
• Calcium channel blockers that affect AV node (e.g., verapamil, diltiazem): risk of severe bradycardia.
• Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): increased nebivolol plasma levels.

Moderate Interactions (Monitor Closely)

• Diuretics: may enhance hypotensive effect.
• ACE inhibitors or ARBs: additive blood‑pressure lowering.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may reduce antihypertensive efficacy.